John A. Purvis

Learn More
OBJECTIVES The purpose of this study was to assess the efficacy of 150 mg of aspirin plus 100 mg of alteplase, administered as two intravenous bolus injections of 50 mg each given 30 min apart, and followed by intravenous heparin, on infarct-related coronary artery patency (Thrombolysis in Myocardial Infarction [TIMI] flow grade 3). BACKGROUND Previous(More)
OBJECTIVE The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C-->T polymorphism in MTHFR. METHODS We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C-->T polymorphism, from an original cohort of 404(More)
BACKGROUND We recently reported that the elevated blood pressure (BP) observed in patients with cardiovascular disease who are homozygous for the 677C→T polymorphism (TT genotype) in the gene encoding methylenetetrahydrofolate reductase (MTHFR) was responsive to supplementation with riboflavin-the cofactor for MTHFR. OBJECTIVE The objective was to(More)
We have investigated the timescale of increased lipid peroxidation following successful early thrombolytic therapy for acute myocardial infarction and report for the first time reciprocal changes in plasma chain-breaking antioxidants. Sixty-seven patients were recruited following a first acute myocardial infarction within 6 h of the onset of symptoms and(More)
Fifty-nine consecutive patients presenting within 6 hours of the onset of symptoms of an acute myocardial infarction were treated with 150 mg of soluble aspirin orally, and either 70 or 100 mg of alteplase divided into 2 intravenous bolus injections separated by 30 minutes. Dosage regimens were either 20 followed by 50 mg (group A), 50 followed by 20 mg(More)
This review has dealt primarily with the rationale and results associated with the bolus administration of rt-PA and related compounds. The aim of bolus therapy is to increase the proportion of patients treated with thrombolytic therapy who can enjoy the benefits of early, complete, and sustained coronary patency. Bolus rt-PA appears to be a promising(More)